GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin.57, 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Compton CC, Greene FL. The staging of colorectal cancer. 2004 and beyond. CA Cancer J. Clin.54, 295–308 (2004).
   PubMed Web of Science ®Google Scholar
• Greene FL. AJCC Cancer Staging Manual. (6th Edition). Springer, NY, USA (2002).
   Google Scholar
• Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma. a meta-analysis. Ann. Surg. Oncol.13, 1386–1392 (2006).
   PubMedGoogle Scholar
• Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J. Mol. Diagn.9, 563–571 (2007).
   PubMedGoogle Scholar
• Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med.352, 476–487 (2005).
   PubMed Web of Science ®Google Scholar
• Ries LA, Wingo PA, Miller DS et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer88, 2398–2424 (2000).
   PubMed Web of Science ®Google Scholar
• Sobrero A, Kerr D, B Glimelius et al. New directions in the treatment of colorectal cancer. a look to the future. Eur. J. Cancer36, 559–566 (2000).
   PubMedGoogle Scholar
• Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J. Clin.57, 168–185 (2007).
   PubMed Web of Science ®Google Scholar
• Allee PE, Tepper JE, Gunderson LL, Munzenrider JE. Postoperative radiation therapy for incompletely resected colorectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.17, 1171–1176 (1989).
   PubMed Web of Science ®Google Scholar
• Dukes CE, Bussey HJ. The spread of rectal cancer and its effect on prognosis. Br. J. Cancer12, 309–320 (1958).
   PubMed Web of Science ®Google Scholar
• Galandiuk S, Wieand HS, Moertel CG et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg. Gynecol. Obstet.174, 27–32 (1992).
   PubMedGoogle Scholar
• Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT. Potentially curative surgery of colon cancer. the influence of blood vessel invasion. J. Clin. Oncol.6, 119–127 (1988).
   PubMed Web of Science ®Google Scholar
• Newland RC, Chapuis PH, Pheils MT, MacPherson JG. The relationship of survival to staging and grading of colorectal carcinoma. a prospective study of 503 cases. Cancer47, 1424–1429 (1981).
   PubMedGoogle Scholar
• Olson RM, Perencevich NP, Malcolm AW, Chaffey JT, Wilson RE. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer45, 2969–2974 (1980).
   PubMed Web of Science ®Google Scholar
• Phillips RK, Hittinger R, Blesovsky L, Fry JS, Fielding LP. Large bowel cancer. surgical pathology and its relationship to survival. Br. J. Surg.71, 604–610 (1984).
   PubMed Web of Science ®Google Scholar
• Rubio CA, Emas S, Nylander G. A critical reappraisal of Dukes’ classification. Surg. Gynecol. Obstet.145, 682–684 (1977).
   PubMedGoogle Scholar
• Sinicrope FA, Sugarman SM. Role of adjuvant therapy in surgically resected colorectal carcinoma. Gastroenterology109, 984–993 (1995).
   PubMed Web of Science ®Google Scholar
• Willett CG, Tepper JE, Cohen AM, Orlow E, Welch CE. Failure patterns following curative resection of colonic carcinoma. Ann. Surg.200, 685–690 (1984).
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, L Mounedji-Boudiaf et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350, 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Bilchik AJ, Hoon DS, S Saha et al. Prognostic impact of micrometastases in colon cancer. interim results of a prospective multicenter trial. Ann. Surg.246, 568–575; discussion 575–577 (2007).
   PubMed Web of Science ®Google Scholar
• Mamounas E, Wieand S, N Wolmark et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer. Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol.17, 1349–1355 (1999).
   PubMed Web of Science ®Google Scholar
• Quasar Collaborative Group, Gray R, Barnwell J et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer. a randomised study. Lancet370, 2020–2029 (2007).
   PubMed Web of Science ®Google Scholar
• Iddings D, Bilchik A. The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. J. Surg. Oncol.96, 671–677 (2007).
   PubMedGoogle Scholar
• Ratto C, Sofo L, Ippoliti M et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis. Colon Rectum42, 143–154; discussion 154–158 (1999).
   PubMed Web of Science ®Google Scholar
• Buie WD, Rothernberger DA. Surveillance after curative resection o colorectal cancer. individualing follow-up. Gastrointest. Endosc. Clin. N. Am.3, 691–713 (1993).
   Google Scholar
• Sloane JP. Molecules and micrometastases. Lancet345, 1255–6 (1995).
   PubMed Web of Science ®Google Scholar
• Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW Jr. Identification of occult micrometastases in pericolic lymph nodes of Duke’s B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer73, 563–569 (1994).
   PubMed Web of Science ®Google Scholar
• Liefers GJ, AM Cleton-Jansen, CJ van de Velde et al. Micrometastases and survival in stage II colorectal cancer. N. Engl. J. Med.339, 223–228 (1998).
   PubMed Web of Science ®Google Scholar
• Andre T, Sargent D, Tabernero J et al. Current issues in adjuvant treatment of stage II colon cancer. Ann. Surg. Oncol.13, 887–898 (2006).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C. Targeted agents for adjuvant therapy of colon cancer. Semin. Oncol.33, S42–S45 (2006).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin. Oncol.34, S37–S40 (2007).
   Google Scholar
• Fuchs CS, Mayer RJ. Adjuvant chemotherapy for colon and rectal cancer. Semin. Oncol.22, 472–487 (1995).
   PubMed Web of Science ®Google Scholar
• Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med.324, 709–715 (1991).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med.322, 352–358 (1990).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, B Fisher et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer. results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J. Clin. Oncol.11, 1879–1887 (1993).
   PubMed Web of Science ®Google Scholar
• Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol.27(22), 3677–3683 (2009).
   PubMed Web of Science ®Google Scholar
• Benson AB, 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol.22, 3408–3419 (2004).
   PubMed Web of Science ®Google Scholar
• Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer. a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J. Clin. Oncol.22, 3395–3407 (2004).
   PubMed Web of Science ®Google Scholar
• Winn R, McClure J. The NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw.1, 9 (2005).
   Google Scholar
• Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev. Mol. Diagn.5, 701–713 (2005).
   PubMed Web of Science ®Google Scholar
• Gelmann A, Desnoyers R, Cagir B, Weinberg D, Boman BM, Waldman SA. Colorectal cancer staging and adjuvant chemotherapy. Expert Opin. Pharmacother.1, 737–755 (2000).
   PubMedGoogle Scholar
• Waldman SA, Hyslop T, S Schulz et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA301, 745–752 (2009).
   PubMed Web of Science ®Google Scholar
• Cagir B, Gelmann A, J Park et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann. Intern. Med.131, 805–812 (1999).
   PubMed Web of Science ®Google Scholar
• Almenoff JS, Williams SI, Scheving LA, Judd AK, Schoolnik GK. Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors. Mol. Microbiol.8, 865–873 (1993).
   PubMed Web of Science ®Google Scholar
• Carrithers SL, Barber MT, Biswas S et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc. Natl Acad. Sci. USA93, 14827–14832 (1996).
   PubMed Web of Science ®Google Scholar
• Carrithers SL, Parkinson SJ, Goldstein S, Park P, Robertson DC, Waldman SA. Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology107, 1653–1661 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen MB, Guarino A, Shukla R, Giannella RA. Age-related differences in receptors for Escherichia coli heat-stable enterotoxin in the small and large intestine of children. Gastroenterology94, 367–373 (1988).
   PubMed Web of Science ®Google Scholar
• Cohen MB, Moyer MS, Luttrell M, Giannella RA. The immature rat small intestine exhibits an increased sensitivity and response to Escherichia coli heat-stable enterotoxin. Pediatr. Res.20, 555–560 (1986).
   PubMed Web of Science ®Google Scholar
• Guarino A, Cohen M, Thompson M, Dharmsathaphorn K, Giannella R. T84 cell receptor binding and guanyl cyclase activation by Escherichia coli heat-stable toxin. Am. J. Physiol.253, G775–G780 (1987).
   PubMedGoogle Scholar
• Guarino A, Cohen MB, Giannella RA. Small and large intestinal guanylate cyclase activity in children. effect of age and stimulation by Escherichia coli heat-stable enterotoxin. Pediatr. Res.21, 551–555 (1987).
   PubMed Web of Science ®Google Scholar
• Guarino A, Cohen MB, Overmann G, Thompson MR, Giannella RA. Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig. Dis. Sci.32, 1017–1026 (1987).
   PubMed Web of Science ®Google Scholar
• Lucas KA, Pitari GM, Kazerounian S et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev.52, 375–414 (2000).
   PubMed Web of Science ®Google Scholar
• Rao MC, Guandalini S, Smith PL, Field M. Mode of action of heat-stable Escherichia coli enterotoxin. Tissue and subcellular specificities and role of cyclic GMP. Biochim. Biophys. Acta632, 35–46 (1980).
   PubMed Web of Science ®Google Scholar
• Carrithers SL, Ott CE, Hill MJ et al. Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor. Kidney Int.65, 40–53 (2004).
   PubMed Web of Science ®Google Scholar
• Field M. Mechanisms of action of cholera and Escherichia coli enterotoxins. Am. J. Clin. Nutr.32, 189–196 (1979).
   PubMedGoogle Scholar
• Field M, Graf LH Jr, Laird WJ, Smith PL. Heat-stable enterotoxin of Escherichia coli.in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine. Proc. Natl Acad. Sci. USA75, 2800–2804 (1978).
   PubMed Web of Science ®Google Scholar
• Guerrant RL, Hughes JM, Chang B, Robertson DC, Murad F. Activation of intestinal guanylate cyclase by heat-stable enterotoxin of Escherichia coli. Studies of tissue specificity, potential receptors, and intermediates. J. Infect. Dis.142, 220–228 (1980).
   PubMed Web of Science ®Google Scholar
• Hughes JM, Murad F, Chang B, Guerrant RL. Role of cyclic GMP in the action of heat-stable enterotoxin of Escherichia coli.Nature271, 755–756 (1978).
   PubMed Web of Science ®Google Scholar
• Kuno T, Kamisaki Y, Waldman SA, Gariepy J, Schoolnik G, Murad F. Characterization of the receptor for heat-stable enterotoxin from Escherichia coli in rat intestine. J. Biol. Chem.261, 1470–1476 (1986).
   PubMed Web of Science ®Google Scholar
• Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell63, 941–948 (1990).
   PubMed Web of Science ®Google Scholar
• Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am. J. Pathol.171, 1847–1858 (2007).
   PubMed Web of Science ®Google Scholar
• Li P, Lin JE, Snook AE et al. Colorectal cancer as a paracrine deficiency syndrome amenable to oral hormone replacement therapy. Clin. Trans. Sci.1, 163–167 (2008).
   PubMedGoogle Scholar
• Li P, Lin JE, Snook AE, Schulz S, Pitari GM, Waldman SA. Colorectal cancer is a paracrine deficiency syndrome which can be prevented and treated by oral hormone replacement therapy. Curr. Mol. Pharm.1(2), 163–167. (2008).
   Google Scholar
• Li P, Schulz S, A Bombonati et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology133, 599–607 (2007).
   PubMed Web of Science ®Google Scholar
• Lin EJ, Li P, Snook AE, Schulz S, Pitari GM, Waldman SA. Guanylyl cyclase C in colorectal cancer. susceptibility gene and potential therapeutic target. Future Oncol.5(4), 509–522 (2009).
   PubMed Web of Science ®Google Scholar
• Lin JE, Li P, Snook AE et al. GUCY2C establishes lineage dependence in intestinal tumorigenesis through AKT. Gastroenterology (2009) (In press).
   Google Scholar
• Pitari GM, Baksh RI, Harris DM, Li P, Kazerounian S, Waldman SA. Interruption of homologous desensitization in cyclic guanosine 3´,5´-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res.65, 11129–11135 (2005).
   PubMed Web of Science ®Google Scholar
• Pitari GM, MD Di Guglielmo, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc. Natl Acad. Sci. USA98, 7846–7851 (2001).
   PubMed Web of Science ®Google Scholar
• Pitari GM, Li P, Lin JE et al. The paracrine hormone hypothesis of colorectal cancer. Clin. Pharmacol. Ther.82, 441–447 (2007).
   PubMed Web of Science ®Google Scholar
• Pitari GM, Lin JE, Shah FJ et al. Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis29, 1601–1607 (2008).
   PubMed Web of Science ®Google Scholar
• Pitari GM, Zingman LV, Hodgson DM et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc. Natl Acad. Sci. USA100, 2695–2699 (2003).
   PubMed Web of Science ®Google Scholar
• Shailubhai K, Yu HH, Karunanandaa K et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res.60, 5151–5157 (2000).
   PubMed Web of Science ®Google Scholar
• Steinbrecher KA, Wowk SA, Rudolph JA, Witte DP, Cohen MB. Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am. J. Pathol.161, 2169–2178 (2002).
   PubMed Web of Science ®Google Scholar
• Birkenkamp-Demtroder K, Christensen LL, Harder Olesen S et al. Gene expression in colorectal cancer. Cancer Res.62, 4352–4363 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen MB, Hawkins JA, Witte DP. Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Lab. Invest.78, 101–108 (1998).
   PubMed Web of Science ®Google Scholar
• Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res.61, 3124–3130 (2001).
   PubMed Web of Science ®Google Scholar
• Steinbrecher KA, Tuohy TM, Heppner Goss K et al. Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem. Biophys. Res. Commun.273, 225–230 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson C, Schulz S, Hyslop, Waldman SA, Silencing of guanylin and uroguanylin expression in colon cancer. (2009) (In press).
   Google Scholar
• Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum. Pathol.36, 170–179 (2005).
   PubMed Web of Science ®Google Scholar
• Fava TA, Desnoyers R, S Schulz et al. Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood. J. Clin. Oncol.19, 3951–3959 (2001).
   PubMed Web of Science ®Google Scholar
• Waldman SA, Barber M, Pearlman J, Park J, George R, Parkinson SJ. Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro.Cancer Epidemiol. Biomarkers Prev.7, 505–514 (1998).
   PubMed Web of Science ®Google Scholar
• Waldman SA, Cagir B, J Rakinic et al. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis. Colon Rectum41, 310–315 (1998).
   PubMed Web of Science ®Google Scholar
• Schulz S, Hyslop T, Haaf J et al. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin. Cancer Res.12, 4545–4552 (2006).
   PubMedGoogle Scholar
• Witek ME, Nielsen K, R Walters et al. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin. Cancer Res.11, 8549–8556 (2005).
   PubMedGoogle Scholar
• Phillips B, Ball C, D Sackett et al.Levels of Evidence. Oxford Centre for Evidence-Based Medicine, Oxford, UK (2009).
   Google Scholar
• Chervoneva I, Li Y, Iglewicz B, Waldman S, Hyslop T. Relative quantification based on logistic models for individual polymerase chain reactions. Stat. Med.26, 5596–5611 (2007).
   PubMedGoogle Scholar
• Moertel CG, O’Fallon JR, Go VL, O’Connell MJ, Thynne GS. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer58, 603–610 (1986).
   PubMed Web of Science ®Google Scholar
• Punt CJ, Buyse M, Kohne CH et al. Endpoints in adjuvant treatment trials. A systematic review of the literature in colon cancer and proposed definitions for future trials. J. Natl Cancer Inst.99, 998–1003 (2007).
   PubMed Web of Science ®Google Scholar
• Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed. a secondary survey of intergroup trial INT-0089. J. Clin. Oncol.21, 2912–2919 (2003).
   PubMed Web of Science ®Google Scholar
• Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann. Surg. Oncol.10, 65–71 (2003).
   PubMed Web of Science ®Google Scholar
• Brown HG, Luckasevic TM, Medich DS, Celebrezze JP, Jones SM. Efficacy of manual dissection of lymph nodes in colon cancer resections. Mod. Pathol.17, 402–406 (2004).
   PubMed Web of Science ®Google Scholar
• Herrera-Ornelas L, Justiniano J, Castillo N, Petrelli NJ, Stulc JP, Mittelman A. Metastases in small lymph nodes from colon cancer. Arch. Surg.122, 1253–1256 (1987).
   PubMed Web of Science ®Google Scholar
• Hitchcock CL, Sampsel J, Young DC, Martin EW Jr, Arnold MW. Limitations with light microscopy in the detection of colorectal cancer cells. Dis. Colon Rectum42, 1046–1052 (1999).
   PubMedGoogle Scholar
• Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat. Protoc.1, 1559–1582 (2006).
   PubMed Web of Science ®Google Scholar
• Abati A, Liotta LA. Looking forward in diagnostic pathology. the molecular superhighway. Cancer78, 1–3 (1996).
   PubMedGoogle Scholar
• Krishna R, Herman G, Wagner JA. Accelerating drug development using biomarkers. a case study with sitagliptin, a novel DPP4 inhibitor for Type 2 diabetes. AAPS J.10, 401–409 (2008).
   PubMed Web of Science ®Google Scholar
• Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res.23, 312–328 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JW, Weiner RS, Sailstad JM et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development. a conference report. Pharm. Res.22, 499–511 (2005).
   PubMed Web of Science ®Google Scholar
• Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Dis. Markers18, 41–46 (2002).
   PubMed Web of Science ®Google Scholar
• Wagner JA. Back to the future. Driving innovation in drug development. Clin. Pharmacol. Ther.83, 199–202 (2008).
   PubMedGoogle Scholar
• Wagner JA. Strategic approach to fit-for-purpose biomarkers in drug development. Ann. Rev. Pharmacol. Toxicol.48, 631–651 (2008).
   PubMed Web of Science ®Google Scholar
• Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther.81, 104–107 (2007).
   PubMed Web of Science ®Google Scholar
• Williams SA, Slavin DE, Wagner JA, Webster CJ. A cost–effectiveness approach to the qualification and acceptance of biomarkers. Nat. Rev. Drug Discov.5, 897–902 (2006).
   PubMed Web of Science ®Google Scholar